Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus SOX for advanced gastric or gastroesophageal junction adenocarcinoma with genomic profiling
ChiCTR-IIR-17010609Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of latanoprost in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Started May 2016; status: recruiting.
02
Drugs
latanoprost
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-IIR-17010609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17010609.